CMS Entry id: 2709 | Channel: Blog landing page | Template: blog/index

Login
Facebook YouTube Twitter Linkedin
Facebook YouTube Twitter Linkedin

Blog

Bringing a drug to market: How do we find and monitor suitable patients?

What will happen when we eventually develop a treatment that halts the development of early Alzheimer’s disease? Being first-in-class, pharmacovigilance post-marketing will be vitally important to ascertain the long-term effects of the drug: both positive and negative. We need to be prepared for a breakthrough and pre-emptively identify technologies which can find the right patients likely to benefit from the drug and monitor treatment effects in the real world. 

web-based testing, wearables, voice recognition, voice, virtual clinical trials, technology, swm, subjective measures, stigma, social cognition, smartphones, schizophrenia research, schizophrenia, research funding, research, remote testing, regulations, recruitment, prodromal, pro-cognitive, presenteeism, precision psychiatry, pre-clinical, poster, personalised medicine, patient-centric, patient recruitment, parkinson's disease, pal, paired associates learning, ots, online, occupational health, objective measures, normative data, neurotech, neuroscience, near-patient testing, multiple sclerosis, ms, modelling, mental wellbeing, mental health at work, mental health, mci, major depression, machine learning, longitudinal, ied, hot cognition, high frequency, healthcare, guide, funding, ert, epidemiology, emotion recognition, ebt, ebbinghaus, early career researchers, early alzheimer's disease, drug development, digital tools, digital health, depression, dementia, cognitive wellbeing, cognitive testing, cognitive science, cognitive safety, cognitive research, cognitive load, cognitive impairment, cognitive function, cognitive dysfunction, cognitive deficits, cognitive biomarkers, cognitive assessment, cognition kit, cognition, cns summit, clinical trials, clinical trial, cias, cgt, cantab testimonial, cantab research grant, cantab for clinical trials, cantab, brain health, biomarkers, awards, automatic speech recognition, autism, attention, asd, alzheimer's disease, affective cognition, adolescents, absenteeism,